Overview

Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer

Status:
Unknown status

Trial end date:
2016-03-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to evaluate and compare safety and effectiveness of Chemotherapy in Paclitaxel plus raltitrexed plug compare with taxol second-line treatment for advanced gastric cancer

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Fudan University

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel
Raltitrexed

Criteria

Inclusion Criteria:

1.18~75 years old 2.Pathological diagnosis of gastric cancer or gastroesophageal junction
adenocarcinoma 3.patient failed after The first line treatment of 5-Fu and platinum
,patient relapse half year after using 5 - Fu and platinum as Postoperative adjuvant
chemotherapy 4.ECOG 0-1 5.At least one measurable objective tumor lesions
6.ANC≥1.5*109/L；PLT≥80*109/L；HB≥90g/L；TBI≤1.5(UNL); ALT、AST≤1.5ULN； Cr≤ULN；Ccr≥60ml/min
7.Expected survival period for 3 months or more 8. patients with voluntary participation,
and sign the informed consent

Exclusion Criteria:

1. Recurrence after transfer have received taxol or docetaxel as first-line
chemotherapy,If the adjuvant chemotherapy with paclitaxel,From the last chemotherapy
for 6 months or less

2. With uncontrollable large pleural or peritoneal effusion

3. In the near future has a history of myocardial infarction (3 months)

4. Malignant tumour of the past five years with other organizations to source, but the
full treatment of cervical carcinoma in situ and except skin basal cell carcinoma and
squamous cell carcinomas;

5. With brain metastasis

6. Severe uncontrolled medical disease or acute infection

7. Pregnancy or breast-feeding women

8. Has a long history of chronic diarrhea, or now complete intestinal obstruction
patients